Literature DB >> 15673517

Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data.

Jaap T van Dissel1, Nanda de Groot1, Charles Mh Hensgens1, Sandra Numan1, Ed J Kuijper1, Peter Veldkamp1, Jan van 't Wout1.   

Abstract

In a pilot study, the feasibility of immune whey protein concentrate (40%; immune WPC-40) to aid the prevention of relapse of Clostridium difficile diarrhoea was evaluated. Immune WPC-40 was made from milk after immunization of Holstein-Frisian cows with C. difficile-inactivated toxins and killed whole-cell C. difficile. Immune WPC-40 contained a high concentration of specific sIgA antibodies, and was effective in neutralizing the cytotoxic effect of C. difficile toxins in cell assays in vitro. Immune WPC-40 conferred protection from otherwise lethal C. difficile-associated caecitis in hamsters. To obtain preliminary data in humans, 16 patients (10 male; median 57 years) with toxin- and culture-confirmed C. difficile diarrhoea were enrolled in an uncontrolled cohort study. Nine had a history of relapsing C. difficile diarrhoea. After completion of standard antibiotic treatment, the patients received immune WPC-40 TID for 2 weeks; it was well tolerated and no treatment-related adverse effects were observed. In all but one case, C. difficile toxins had disappeared from the faeces upon completion of treatment. During a follow-up period of median 333 days (range 35 days to 1 year), none of the patients had suffered another episode of C. difficile diarrhoea. These preliminary data suggest that immune whey protein concentrate-40 may be of help in the prevention of relapse of C. difficile diarrhoea.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15673517     DOI: 10.1099/jmm.0.45773-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  37 in total

1.  Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.

Authors:  April Roberts; Joanna McGlashan; Ibrahim Al-Abdulla; Roger Ling; Harriet Denton; Steve Green; Ruth Coxon; John Landon; Clifford Shone
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

Review 2.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses.

Authors:  Sandra C Numan; Peter Veldkamp; Ed J Kuijper; Renate J van den Berg; Jaap T van Dissel
Journal:  Gut       Date:  2007-06       Impact factor: 23.059

Review 4.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

Review 5.  Recurrent Clostridium difficile infection: what are the treatment options?

Authors:  Claire M F van Nispen tot Pannerden; Annelies Verbon; Ernst J Kuipers
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 6.  Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections.

Authors:  Michael G Dieterle; Krishna Rao; Vincent B Young
Journal:  Ann N Y Acad Sci       Date:  2018-09-21       Impact factor: 5.691

Review 7.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

8.  Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.

Authors:  Kasper Krogh Andersen; Nika M Strokappe; Anna Hultberg; Kai Truusalu; Imbi Smidt; Raik-Hiio Mikelsaar; Marika Mikelsaar; Theo Verrips; Lennart Hammarström; Harold Marcotte
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

9.  New antimicrobial agents for patients with Clostridium difficile infections.

Authors:  John G Bartlett
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

10.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.